Cornerstone Robotics Valuation, Funding & Investors

Cornerstone Robotics is valued at $1B as of November 2025.

Last Cornerstone Robotics valuation

$1B

Undisclosed stage · Nov 2025

Last Cornerstone Robotics funding round

$700M

Strategic investment · Sep 2026

Cumulative funding Cornerstone Robotics raised

$1.2B

across 6 funding rounds

Key investors in Cornerstone Robotics

  • Qiming Venture Partners
  • K2VC
  • Longzhu Capital
  • Gaorong Capital
  • Lilly Asia Ventures
  • Qingsong Capital

Cornerstone Robotics Overview

About Cornerstone Robotics

Cornerstone Robotics is a Shenzhen-based developer of surgical robots enhancing minimally invasive procedures in Chinese hospitals. The company produces the Toumai system for laparoscopic surgeries, approved by NMPA for colorectal and urology applications. Cornerstone Robotics partners with tertiary hospitals in Beijing and Shanghai for clinical trials and deployments.


Founded

2019

HQ

Hong KongHong Kong

Website

csrbtx.com

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$1B (Nov 2025)

Cornerstone Robotics Valuation

Cornerstone Robotics is currently valued at $1B, based on its undisclosed-stage round in November 2025.

The $200M round was led by Hong Kong Investment Corporation Limited, with participation from ZhenFund, Gaorong Capital, Qiming Venture Partners, BridgeOne Capital and K2VC.

Cornerstone Robotics' valuation has grown 1.4x from $694M at its Series B in November 2021 to $1B in November 2025, across 2 priced rounds.

Cornerstone Robotics valuation by funding round

Cornerstone Robotics valuation by funding round
DateStageValuation
Nov 2025Undisclosed stage$1B
Nov 2021Series B$694M

Cornerstone Robotics Funding History

Cornerstone Robotics has raised a total of $1.2B across 6 funding rounds.

Cornerstone Robotics' first fundraising round was a $17M Series A in January 2021. The most recent completed round was a $700M strategic investment round in September 2026.

Cornerstone Robotics funding rounds

Cornerstone Robotics funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2026Strategic investmentMedtronic (lead)$700M-Medtronic agreed on September 1, 2026 to make an approximately $700 million strategic investment in Cornerstone Robotics as part of a broader partnership that also gives Medtronic the right to distribute Cornerstone’s Sentire surgical system in select markets outside the U.S. where the system is market approved. The transaction is structured around convertible preferred shares and includes distribution rights for Sentire alongside Medtronic’s Hugo robotic-assisted surgery system, creating a dual-platform robotic surgery portfolio aimed at expanding access and giving surgeons and health systems more choice and flexibility. The strategic rationale is to accelerate global adoption of robotic-assisted surgery by combining Medtronic’s commercial reach with Cornerstone’s surgical robotics technology. The partnership is intended to expand access in international markets and strengthen Medtronic’s robotic-assisted surgery offering, with Sentire positioned as a complement to Hugo rather than a replacement. Cornerstone Robotics is a Hong Kong-founded surgical robotics company focused on minimally invasive surgery. Its Sentire system is approved in China, Europe, and Singapore, and the company has described its technology as including fully in-house developed core systems and advanced imaging and force-feedback capabilities. The transaction follows Cornerstone’s continued commercialization and international expansion efforts, supported by its manufacturing and R&D footprint in China.
Nov 2025Undisclosed stageHong Kong Investment Corporation Limited (lead); ZhenFund; Gaorong Capital; Qiming Venture Partners; BridgeOne Capital; K2VC$200M$1BCornerstone Robotics, founded in 2019, is a Hong Kong-based leader in surgical robotics, developing the Sentire Endoscopic Surgical System, a multi-arm platform approved by China's NMPA in 2024 and in clinical use in China, Hong Kong, and Europe, with ongoing trials in the UK. The company focuses on full-stack in-house R&D, vertical integration, and localization of parts production in Shenzhen to rival Intuitive Surgical's da Vinci at lower cost, emphasizing accessibility for low- and middle-income markets. In November 2025, Cornerstone closed an oversubscribed financing round of approximately US$200 million, led by Hong Kong Investment Corporation Limited, with participation from a global strategic investor, sovereign wealth funds, and existing investors including Qiming Venture Partners, BridgeOne Capital, Gaorong Capital, and K2VC. This Series D round follows a $70 million Series C in January 2025 led by EQT, marking one of Asia's largest medtech raises that year. Proceeds will accelerate commercialization in China and overseas, support next-generation R&D, clinical registrations, and global partnerships for market entry and distribution. The Sentire system features a familiar interface for da Vinci users, enabling telesurgery achievements like multi-site intercontinental procedures and AI-driven autonomous tasks such as gauze picking. With hubs in Hong Kong, Shenzhen, Beijing, Shanghai, London, and Portsmouth, Cornerstone employs over 200 engineers and produces up to 200 systems annually at its Shenzhen plant. Investors highlight confidence in its technical roadmap, clinical progress, and Hong Kong's role in surgical robotics innovation.
Jan 2025Series CEQT (lead); Innovation and Technology Venture Fund; Longzhu Capital; Qingsong Capital; Qiming Venture Partners; Alpha JWC Ventures; K2VC; CTS Capital; eGarden Ventures$70M-Cornerstone Robotics, a Hong Kong-based surgical robotics company founded in 2019, announced a Series C financing round of over $70 million led by EQT on January 13, 2025, with participation from Qiming Venture Partners, Alpha JWC Ventures, the Innovation and Technology Venture Fund, eGarden Ventures, CTS Funds, K2VC, and Long-Z Capital. The company develops the Sentire Endoscopic Surgical System, a multiarm platform designed for minimally invasive surgical procedures. In September 2024, the system received approval from China's National Medical Products Administration, and clinical trials began in the United Kingdom at Queen Alexandra Hospital in Portsmouth in June 2025 to assess safety and efficacy in colorectal and urologic procedures. The Series C funding is intended to accelerate commercialization, develop new surgical robotics products, conduct clinical trials, obtain regulatory approvals, and promote global adoption of advanced robotic surgical solutions across Europe, Southeast Asia, and other key markets. Notably, the Innovation and Technology Venture Fund, backed by Hong Kong's government, participated in this round, signaling official endorsement of the company's innovation and commercialization capabilities. The company operates with over 200 engineers in its Shenzhen facility spanning 150,000 square feet, and in November 2025 closed an additional oversubscribed financing round of approximately $200 million from a global strategic investor, sovereign wealth funds, and existing shareholders.
Jun 2023Series BLongzhu Capital; Qingsong Capital; Qiming Venture Partners; Lenovo Capital and Incubator Group (LCIG); BridgeOne Capital; K2VC; Lilly Asia Ventures; CTS Capital$112M-Cornerstone Robotics, founded in 2019, develops surgical robotics including its flagship Sentire® laparoscopic system, approved by China's NMPA and adopted in hospitals in mainland China, Hong Kong, and Europe. The company maintains full vertical integration with in-house production of core components like robotic systems, imaging, energy platforms, and instruments. Cornerstone's progress includes preclinical/clinical studies by 2020, NMPA approval, and innovations like a 2025 multifunctional embodied-intelligence platform with The Chinese University of Hong Kong, enabling the world's first autonomous surgical demonstration on Sentire®. On June 30, 2023, Cornerstone Robotics closed a Series C funding round raising $110.08M (sources vary slightly to ~$111.7M), led by investors including BridgeOne Capital, K2VC, Lenovo Capital and Incubator Group (LCIG), Lilly Asia Ventures, Longzhu Capital, Qiming Venture Partners, Qingsong Capital, and New World Development. Total funding across rounds reached $205.38M over 4 rounds by that date. The company focused on clinical trials, commercialization, and global expansion post-round. Subsequently, in November 2025, Cornerstone raised an oversubscribed ~$200M round led by Hong Kong Investment Corporation (HKIC), with a global strategic investor, sovereign wealth funds, and existing backers like Qiming Venture Partners, BridgeOne Capital, and K2VC, to accelerate commercialization of Sentire® and next-gen development. This positioned Cornerstone as a leading Chinese surgical robotics unicorn amid growing market adoption.
Nov 2021Series BLongzhu Capital; Gaorong Capital; New World Group; Qiming Venture Partners; Qingsong Fund; K2VC; Lilly Asia Ventures$78M$694MCornerstone Robotics is a leading surgical robotics company founded in September 2019 by world-class surgical robotics experts. The company develops innovative minimally invasive surgical robotic systems, with its flagship product being the Sentire Endoscopic Surgical System, designed to make high-quality surgical care more accessible globally. The company established R&D centers in Shenzhen, Hong Kong, and the United States, assembling professional teams of hundreds of people and mastering core technologies including mechanical architecture, electrical architecture, software architecture, complex algorithms, and visual imaging systems. In November 2021, Cornerstone Robotics completed a Series B financing round raising $78.4 million (500 million yuan). The round was led by prominent investors including Meituan's DragonBall Capital, Lilly Asia Ventures, and New World Development Group, with continued participation from previous shareholders Qiming Venture Partners, China TsingSong Capital, Gaorong Capital, and K2VC. The company was valued at $694 million at the time of this Series B round. The Series B proceeds were designated for product R&D, clinical trials, marketing promotion, new product layout, and construction of cutting-edge technology platforms for surgical robotics. By 2021, Cornerstone had completed development of porous laparoscopic surgery robotic products and was preparing to enter clinical trial stages. The company has since achieved significant milestones, including receiving approval from China's National Medical Products Administration (NMPA) for the Sentire system and expanding clinical use across leading hospitals in mainland China, Hong Kong, and Europe.
Jan 2021Series AQiming Venture Partners (lead)$17M-Cornerstone Robotics is a surgical robotics company founded in 2019 and headquartered in Hong Kong with operations across the Greater Bay Area, Shenzhen, Beijing, Shanghai, London, and Portsmouth. The company develops the Sentire Endoscopic Surgical System, a multiarm robotic platform designed to make high-quality surgical care more accessible and efficient globally. Its flagship product received approval from China's National Medical Products Administration (NMPA) and has entered clinical use in hospitals across mainland China, Hong Kong, and Europe, with clinical trials ongoing in the United Kingdom as of mid-2024.

Who has invested in Cornerstone Robotics?

18 investors have backed Cornerstone Robotics across its funding rounds, including Qiming Venture Partners, K2VC, Longzhu Capital, Gaorong Capital, Lilly Asia Ventures and Qingsong Capital.

Lead investors include Medtronic, Hong Kong Investment Corporation Limited, EQT and Qiming Venture Partners.


Cornerstone Robotics Investors

Investors in Cornerstone Robotics by funding rounds participated
InvestorHQRoundsRoleFirst check
Qiming Venture PartnersChinaShanghai5LeadJan 2021
K2VCChinaBeijing4ParticipantNov 2021
Longzhu CapitalChinaBeijing3ParticipantNov 2021
Gaorong CapitalChinaBeijing2ParticipantNov 2021
Qingsong CapitalChinaBeijing2ParticipantJun 2023
BridgeOne CapitalChinaShenzhen2ParticipantJun 2023
Lilly Asia VenturesChinaShanghai2ParticipantNov 2021
CTS CapitalChinaChaoyang2ParticipantJun 2023
ZhenFundChinaBeijing1ParticipantNov 2025
Innovation and Technology Venture FundHong KongHong Kong1ParticipantJan 2025
EQTSwedenStockholm1LeadJan 2025
MedtronicUnited StatesMinneapolis, MN1LeadSep 2026
New World GroupUnited KingdomLondon1ParticipantNov 2021

This data is available for Pro users. Sign up to see all 18 Cornerstone Robotics investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Cornerstone Robotics Competitors

Cornerstone Robotics competitors include listed companies like Extreme Vision and Cidi, and private ones like ZD Medtech, Science, Precision Neuroscience and Forterra.

Public and private companies comparable to Cornerstone Robotics
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ZD MedtechChinaShanghaiPrivate--$900M-
ScienceUnited StatesSan Francisco, CAPrivate--$1.5B-
Precision NeuroscienceUnited StatesNew York City, NYPrivate--$543M-
ForterraUnited StatesWashington, DCPrivate-$82M$1B-
Extreme VisionChinaChinaPublicly listed$44M($6M)$1B11.6x
CidiChinaChinaPublicly listed$132M($155M)$1.3B5.0x

Cornerstone Robotics Public Comps

Cornerstone Robotics is still privately-owned, but its public comps include SEER Robotics, Extreme Vision, Enovis, CeriBell, Wandong Medical, iRadimed, Staar Surgical, Mani Inc., Obsidian Therapeutics and Shinva.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
SEER Robotics$66M($6M)13.2x-(156.2x)-
Extreme Vision$44M($6M)22.8x11.6x(163.7x)-
Enovis$2.2B($830M)1.1x1.0x(2.9x)5.7x
CeriBell$89M($50M)9.6x7.9x(17.0x)(14.2x)
Wandong Medical$201M($46M)3.1x3.2x(13.7x)-
iRadimed$84M$28M11.9x11.2x36.3x32.8x
Staar Surgical$239M($37M)3.8x3.0x(24.7x)21.5x
Mani Inc.$193M$60M4.0x3.6x12.9x9.7x

This data is available for Pro users. Sign up to see all Cornerstone Robotics competitors and their valuation data.

Start Free Trial

Common questions about Cornerstone Robotics

When was Cornerstone Robotics founded?Cornerstone Robotics was founded in 2019.
Where is Cornerstone Robotics headquartered?Cornerstone Robotics is headquartered in Hong Kong, Hong Kong.
Is Cornerstone Robotics publicly listed?No, Cornerstone Robotics is a private, VC-backed company.
What is Cornerstone Robotics' valuation?Cornerstone Robotics was last valued at $1B in its undisclosed-stage round in November 2025.
How much funding has Cornerstone Robotics raised?Cornerstone Robotics has raised $1.2B across 6 funding rounds.
What was Cornerstone Robotics' last funding round?Cornerstone Robotics' last funding round was a $700M strategic investment round in September 2026, led by Medtronic.
Who are Cornerstone Robotics' investors?Cornerstone Robotics' investors include Qiming Venture Partners, K2VC, Longzhu Capital, Gaorong Capital, Qingsong Capital, BridgeOne Capital, Lilly Asia Ventures, CTS Capital, ZhenFund, Innovation and Technology Venture Fund and 8 others.
Which companies are comparable to Cornerstone Robotics?Companies comparable to Cornerstone Robotics include ZD Medtech, Science, Precision Neuroscience, Forterra, Extreme Vision and Cidi.

See companies similar to Cornerstone Robotics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial